Gilead Calls Forty Seven Buyout Complementary To Kite, Other IO Efforts
Gilead will pay $4.9bn to acquire Forty Seven and its potential first-in-class anti-CD47 agent magrolimab. A fast-track development effort in myelodysplastic syndrome will be the initial focus for that asset.
You may also be interested in...
Pfizer will gain two clinical-stage immuno-oncology assets targeting the SRRPα-CD47 axis that it hopes could reach the market in the 2025-2030 timeframe.
Shaw cites manufacturing speed and success as competitive edges. The Gilead subsidiary unveiled data at ASCO positioning Tecartus, its second CAR-T therapy, to add B-cell acute lymphoblastic leukemia to label.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.